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Anti‑malarial landscape in Myanmar:
results from a nationally representative survey
among community health workers and the
private sector outlets in 2015/2016
ACTwatch Group1*, , Si Thu Thein2, Hnin Su Su Khin2 and Aung Thi3

Abstract
Background: In 2015/2016, an ACTwatch outlet survey was implemented to assess the anti-malarial and malaria
testing landscape in Myanmar across four domains (Eastern, Central, Coastal, Western regions). Indicators provide an
important benchmark to guide Myanmar’s new National Strategic Plan to eliminate malaria by 2030.
Methods: This was a cross-sectional survey, which employed stratified cluster-random sampling across four regions
in Myanmar. A census of community health workers (CHWs) and private outlets with potential to distribute malaria
testing and/or treatment was conducted. An audit was completed for all anti-malarials, malaria rapid diagnostic tests.
Results: A total of 28,664 outlets were approached and 4416 met the screening criteria. The anti-malarial market
composition comprised CHWs (41.5%), general retailers (27.9%), itinerant drug vendors (11.8%), pharmacies (10.9%),
and private for-profit facilities (7.9%). Availability of different anti-malarials and diagnostic testing among anti-malarialstocking CHWs was as follows: artemisinin-based combination therapy (ACT) (81.3%), chloroquine (67.0%), confirmatory malaria test (77.7%). Less than half of the anti-malarial-stocking private sector had first-line treatment in stock:
ACT (41.7%) chloroquine (41.8%), and malaria diagnostic testing was rare (15.4%). Oral artemisinin monotherapy
(AMT) was available in 27.7% of private sector outlets (Western, 54.1%; Central, 31.4%; Eastern; 25.0%, Coastal; 15.4%).
The private-sector anti-malarial market share comprised ACT (44.0%), chloroquine (26.6%), and oral AMT (19.6%).
Among CHW the market share was ACT (71.6%), chloroquine (22.3%); oral AMT (3.8%). More than half of CHWs could
correctly state the national first-line treatment for uncomplicated falciparum and vivax malaria (59.2 and 56.9%,
respectively) compared to the private sector (15.8 and 13.2%, respectively). Indicators on support and engagement
were as follows for CHWs: reportedly received training on malaria diagnosis (60.7%) or national malaria treatment
guidelines (59.6%), received a supervisory or regulatory visit within 12 months (39.1%), kept records on number of
patients tested or treated for malaria (77.3%). These indicators were less than 20% across the private sector.
Conclusion: CHWs have a strong foundation for achieving malaria goals and their scale-up is merited, however gaps
in malaria commodities and supplies must be addressed. Intensified private sector strategies are urgently needed and
must be scaled up to improve access and coverage of first-line treatments and malaria diagnosis, and remove oral
AMT from the market place. Future policies and interventions on malaria control and elimination in Myanmar should
take these findings into consideration across all phases of implementation.
Keywords: Anti-malarial, Oral artemisinin monotherapy, Artemisinin combination therapy, Chloroquine,
Malaria testing
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Background
Myanmar bears the highest malaria burden in the Greater
Mekong Sub-region (GMS), accounting for around 70%
of reported cases in the region. The incidence of reported
malaria has dropped by about 49% since 2012 (from 8.09
in 2012 to 4.16 in 2015 per 1000 population) [1]. Approximately 16% of Myanmar’s population of 57 million live in
areas of high transmission and another 44% live in areas
of low transmission. Plasmodium falciparum makes up
75% of the parasite species while Plasmodium vivax comprises the other 25% [2].
In 2008, artemisinin-based combination therapy (ACT)
(artemether–lumefantrine [AL], dihydroartemisinin–
piperaquine [DHA-PP] or artesunate-mefloquine
[ASMQ]) was introduced as the first-line treatment for
uncomplicated falciparum malaria and chloroquine has
been the first-line treatment for vivax malaria [2]. The
2012 Myanmar National Treatment Guidelines specify
that a single dose of primaquine should be administered
following confirmed cases of falciparum malaria and
a 14-day dose for radical cure of vivax malaria. Policies
have been implemented for the use of primaquine at varying levels of the health system, allowing the Government
to limit use of primaquine to facilities that are equipped
to either test and/or monitor for signs of glucose-6 phosphate dehydrogenase (G6PD) deficiency. However, as
G6PD testing currently is seldom available in the field,
implementation of this recommendation is limited [3].
To date, several strategies have been in place to ensure
the appropriate diagnosis and treatment of malaria
in Myanmar. One of the key interventions in Myanmar, through the National Malaria Control Programme
(NMCP) as well as several non-governmental organizations (NGOs), has been the training and deployment of
community health workers (CHWs) who complement
the care provided by public healthcare workers in rural
locations, which bear the greatest burden of disease
[1, 2]. Since 2008, the primary role of these CHWs has
been to provide access to confirmatory testing and firstline treatment for patients who present with symptoms
of vivax or falciparum malaria. CHWs are part of public
sector health services, but the providers themselves are
volunteers who depend on the support of a NGO or the
NMCP [4].
In the private sector, where up to 70% of Myanmar’s
population receive treatment [5, 6], several initiatives
have also been in place over recent years to strengthen
malaria case management. In 2010, the Government of
Myanmar developed a set of comprehensive interventions outlined in the “Myanmar Artemisinin Resistance
Containment (MARC)” framework [7]. This included
several activities to strengthen malaria case management services, including the aforementioned scale-up
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of community health workers. As part of the MARC
framework, in 2012, Population Services International
(PSI), a US-based NGO, began implementation of the
artemisinin monotherapy replacement (AMTR) project.
The aim of the AMTR project was to distribute highly
subsidized, first-line ACT into the private sector and
phase out oral artemisinin monotherapy (AMT). Prior
to the intervention, it was estimated that up to 2.4 million packages of oral AMT were being distributed annually in Myanmar [8]. The AMTR project aimed to remove
oral AMT from the market through price competition,
intensive provider behaviour change communication and
other demand-creation activities [5]. This was complemented with a ban in 2012 by the Government of Myanmar on oral AMT in an attempt to curb the widespread
availability and use of this medicine [2]. While subsidized
distribution of ACT occurred throughout the country,
intensive provider behaviour change activities were limited to the eastern region of the country. These concerted
efforts resulted in an increase in availability and distribution of ACT and a reduction in oral AMT in the eastern
regions of Myanmar since 2012, though oral AMT still
has a presence on the market [6]. Furthermore, in 2015,
the AMTR project focused on increasing and scalingup access to malaria confirmatory testing across certain
parts of the country and 60,000 free rapid diagnostic tests
(RDTs) were distributed in the private sector.
Despite several public and private-sector initiatives to
better manage patients through appropriate treatment
and malaria testing, the spread of artemisinin resistance
in Myanmar is now apparent. While artemisinin resistance was thought to only exist on the Thailand–Myanmar border, with many of the aforementioned strategies
over the past half-decade having focused heavily on this
area, resistance has now been detected in areas close to
the border with India [9]. This is of grave concern given
Myanmar is noted as the anti-malarial resistance gateway
to the Indian sub-continent and beyond, and thus is critical to global malaria control and elimination. Detection
of artemisinin resistance, and the country’s commitment
to eliminate malaria by 2030, has prompted an emergency re-assessment of malaria control and elimination
strategies [4].
Key strategies to address malaria control and elimination efforts in Myanmar are outlined in the National
Strategic Plan for Intensifying Malaria Control and
Accelerating Progress towards Malaria Elimination
(2016–2020) [1]. In the public sector, this includes
scale-up of the CHW programme to improve coverage and access to appropriate malaria testing and treatment. The private sector will be increasingly regulated
and licensed, with only ‘selected’ private-sector providers allowed to test and treat patients. Selected outlets
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include pharmacies, private companies and outlets,
who will be trained, supervised, and provided with
malaria commodities, and required to report on caseload data. In addition, the National Strategic Plan specifies that non-licensed drug vendors, except in special
circumstances, will be prohibited from treating malaria
and selling anti-malarial medicines. Several strategies
will be undertaken to regulate non-licensed drug vendors, including enforcement through judiciary officers.
Myanmar will also tighten the ban on oral AMT and
implement police enforcement to stop the sale and distribution of oral AMT.
Timely and relevant anti-malarial market evidence
will be useful to help provide a benchmark for Myanmar’s National Strategic Plan, to help accelerate progress
towards elimination goals in the country and to prioritize strategic areas. Previous studies on the anti-malarial
market and malaria diagnostics have been limited to the
eastern part of the country [6] and, therefore, the performance CHWs and private-sector healthcare providers
for malaria case management services across the country is largely unknown. Furthermore, the performance of
the private sector across different geographical regions
is likely to vary given the lack of uniform strategies to
improve malaria case management, with most activities
happening in the eastern part of the country.
The objective of this paper is to provide evidence to
inform malaria elimination strategy and policy in Myanmar. The paper describes the market for malaria medicines and diagnostics among CHW and across the private
sector. The potential of CHWs and the private sector in
malaria control and elimination efforts is discussed.

Methods
This study was a cross-sectional survey, which employed
stratified cluster-random sampling across four regions
(strata) in Myanmar. The study population consisted of a
census of all anti-malarial stocking outlets in the selected
clusters. The data collection lasted over five months,
from late August 2015 to early January 2016.
ACTwatch project developed the methodology for
this study [10, 11], and the same methodology was
employed for three other studies conducted in the GMS
in 2015/2016 [12]. The ACTwatch project is a multicountry research project, whose goal is to provide highquality evidence on anti-malarial markets all over the
world. Since its inception, the project has developed,
applied and documented several standardized tools and
approaches.
Study population

The study used explicit stratification to provide estimates
within four study regions: (1) Eastern areas were located
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primarily along the eastern border with Thailand and
Yunan Province in China, which were part of the AMTR
intervention programme activities and were expected to
have different outcomes compared to other regions; (2)
Central included areas of central Myanmar that were
adjacent to the AMTR project area in eastern Myanmar but were not part of it, and were expected to have
similar background characteristics to the Eastern region
(in previous outlet survey studies, this region was typically considered a comparison region [6]); (3) Western
included areas within Chin State, Sagaing, and Magway
Regions which formed immediate or proximate borders
with India; and, (4) Coastal, within Rakhine State, Magway, Bago and Ayeyarwaddy Regions which formed the
border with Bangladesh and were part of the coastal area
(Fig. 1).
Eligibility criteria

All outlets with the potential to sell or distribute antimalarial medicines were screened for eligibility. These
included CHWs, private for-profit facilities, pharmacies,
general retailers, and itinerant drug vendors (Table 1). All
outlets, except government health facilities, were eligible
for interview and an anti-malarial or RDT audit if they
met at least one of three study criteria: (1) had one or
more anti-malarial medicines in stock on the day of the
survey; (2) had one or more anti-malarials reportedly in
stock within the three months preceding the survey; and/
or, (3) provided malaria blood testing, either microscopy
or RDT. Public health facilities were excluded from the
study because permission was not received to audit these
facilities.
In this study, private-for-profit health facilities, pharmacies, general retailers, and itinerant drug vendors
comprise the ‘private sector’. CHWs are described separately as a different, public not-for profit channel given
their mode of operation was different.
Sample size

The study was designed to generate estimates for key
market indicators within each region. Minimum sample
size requirements were calculated to estimate, with ±10%
precision, the following indicators: (1) the proportion of
private-sector outlets with ACT availability, among outlets with anti-malarial(s) in stock on the day of the survey; and, (2) the proportion of private-sector outlets with
oral AMT in stock, among outlets with anti-malarial(s)
in stock on the day of the survey. The minimum number
of outlets that needed to be screened was determined
from the required number of anti-malarial stocking
outlets, and the proportion of screened outlets that had
anti-malarial(s) from previous studies [13]. That number was then divided by an estimated average number of
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The sampling frames were constructed using population sizes of clusters because the estimated number
of outlets for each cluster did not exist. The population
figures were used as a proxy measure with the assumption that the number of outlets within a given cluster
were correlated with its population size. To manage the
size of the survey and maintain quality, the survey was
implemented in two phases, with the Eastern and Central regions in phase 1, and Western and Coastal regions
in phase 2. Each phase had a slightly different sampling
approach due to limited availability of population data for
the sampling frame.
Phase 1 data collection used two-stage sampling, where
larger clusters (townships) formed the first-stage sampling frame. From that, 28 townships were randomly
selected using PPS. In the second stage, all wards and village tracts within the selected townships were listed, and
systematic random sampling was used to select a fixed
number of clusters from each township, resulting in the
final sample of 448 clusters.
Phase 2 data collection used one-stage sampling as the
actual population numbers of wards and village tracts
had become available at that time from the 2014 Population and Housing Census. Consequently, the sampling
frame consisted of all clusters (wards and village tracts)
from each region, and a total of 360 clusters were randomly selected using PPS.
Data collection

Central
Eastern
Coastal
Western

Fig. 1 Map of selected clusters

private-sector outlets per cluster to attain the minimal
number of clusters required for the study. In total, 836
clusters were selected across the four regions.
Sampling approach

Clusters were selected using probability proportionate
to size (PPS). A cluster was defined as a ‘ward’ in urban
areas (towns and cities), and as a ‘village tract’ (a cluster
of several villages) in rural areas. On average, 3000–5000
people resided in each cluster, but there were geographical differences.

Two separate interviewer-training sessions were given,
which spanned a total of eight days. The training focused
on identification of outlets and anti-malarial medicines,
informed consent procedures, and step-by-step walkthrough of a full questionnaire.
Within each selected cluster, a census of all outlets with
the potential to sell or distribute anti-malarials and/or
provide malaria blood testing was conducted. The census involved systematically looking for outlets in each
cluster, and using screening questions to identify outlets
for inclusion in the study. Provider interviews and antimalarial audits were conducted in all eligible outlets,
after informed consent procedures.
For each eligible outlet, interviewers conducted an
exhaustive audit of all anti-malarials and RDTs in stock
at the time of the survey. For each and every anti-malarial
medicine, the audit included formulation, brand name,
active ingredients and strengths, manufacturer, and
country of manufacture. The audit also collected information on unit costs of anti-malarials, and amount distributed to individual patients within the previous seven
days. Basic outlet and provider characteristics, including
availability of malaria microscopy, were collected. Questions related to private sector support and engagement
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were also administered to providers. Paper-based questionnaires and field monitoring sheets were used to
record information.
Data entry, processing and analysis

Double data entry and verification was performed using
customised CSPro data entry forms. All data cleaning
and analysis were completed using Stata 13.1 (©StataCorp, College Station, TX, USA). 2014 UNFPA census
data was used to calculate sampling weights, applied at
the township level to account for variations in probability of selection. Stata survey settings were used to reflect
the study design and sampling approach, to compute
estimates, including those at region-level. Standard error
estimation, including application of a finite population
correction, accounted for clustering at the ward/village
track level. Weighting and finite population correction
yielded confidence intervals (CI) used for comparison of
proportions.
Standard indicators were constructed according to
ACTwatch definitions [10, 11, 14]. All audited anti-malarial medicines were verified and classified using information on drug formulation, contents and strengths with
supporting information, including brand or generic name
and manufacturer. Anti-malarials were classified as ACT,
non-artemisinin therapy, and oral or non-oral AMT. A
generic classification of ACT was used as national policy
for uncomplicated falciparum malaria was AL, PHA-PPQ
or ASMQ. Availability of any anti-malarial was defined in
this study as the proportion of outlets stocking at least
one anti-malarial among all screened outlets. Other antimalarial and RDT availability categories were calculated
but restricted to those outlets where at least one antimalarial was audited. For example, ACT availability (the
proportion of ACT-stocking outlets) was measured as
the number of ACT-stocking outlets in the numerator
and the number of anti-malarial stocking outlets in the
denominator.
Market share was defined as the relative distribution
of the anti-malarials sold to individual consumers in the
week preceding the survey. In order to allow for meaningful market share comparisons between products,
information about anti-malarial distribution was standardized to the adult equivalent treatment dose (AETD).
AETD is the amount of active ingredient necessary to
treat a 60-kg adult according to World Health Organization (WHO) treatment guidelines [14]. Volumes distributed were calculated by converting provider reports on
the number of anti-malarials sold in the week prior to the
survey into AETDs. Volumes were the number of AETDs
sold or distributed by a provider in the seven days prior
to the survey. All dosage forms were considered in measuring volumes so as to provide a complete assessment
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of anti-malarial market share. Primaquine distribution
was not included in calculations of total and relative volumes distributed. This is because primaquine is to be
used only in combination with either an ACT for falciparum malaria, or with chloroquine for all other infections. Therefore, similar to the treatment of partner drugs
within an ACT, we only consider volumes distributed for
primaquine’s partner drugs (ACT or chloroquine).
Provider knowledge was assessed by administering
knowledge questions to the senior-most provider at all
anti-malarial-stocking outlets. Providers were asked to
state the national first-line treatment and dosing regimen for uncomplicated falciparum/vivax malaria for a
60-kg adult. Providers citing any first-line ACT as the
first-line treatment for falciparum malaria, or chloroquine for vivax malaria, were classified as having correct
knowledge.
Ethical considerations

The study was approved by PSI Research Ethical Board
registered under the Office of Human Research Protections (OHRP FWA00009154, IRB#00006961). All interviews and product audits were conducted only after
receiving verbal informed consent from the participating
providers. Confidentiality and anonymity was maintained
through all phases of the study, and all standard ethical
guidelines were followed.

Results
A total of 28,664 outlets that had potential to sell/distribute anti-malarial medicines were approached to participate in the survey across the four regions (Table 2).
Of these, 28,267 outlets were screened for stocking antimalarials or malaria diagnostic testing (309 outlets were
closed at the time of visit or closed permanently, and 88
outlet providers refused). Of these, 4416 met the screening criteria and 4395 were interviewed. The number of
interviewed outlets was highest in the more populous
Eastern region (N = 1330), and lowest in Central region
(N = 594). Among the interviewed outlets, 3859 were
found to have at least one anti-malarial in stock at the
time of the survey, 413 outlets had no anti-malarials in
stock at the time but reported having stocked an antimalarial in the past three months, and 123 had malaria
diagnostic testing but no anti-malarials. Among outlets
stocking anti-malarials or malaria tests on the day of survey, 8735 anti-malarial products and 1635 RDTs were
audited.
Among all screened outlets, anti-malarial availability
was as follows: CHW, 45% (N = 2737); private for-profit
facilities, 50.4%, (N = 610); pharmacies, 46.9% (N = 970);
general retailers, 4.6% (N = 22,733); and itinerant drug
vendors, 33.7% (N = 1217).
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Table 1 Outlet types
Community health workers (CHWs)

Village-based volunteers who provide free or highly subsidized health services in remote rural areas. They are
typically linked with government or non-government not-for-profit organizations, and usually receive training, support and supplies

Private sector
Private-for-profit health facilities

General practitioners who operate within privately owned facilities that are licensed by Myanmar’s Ministry of
Health. In some cases, the providers work for Ministry of Health as well and are running these clinics during
their free time

Pharmacies

Pharmacies and drug stores, usually licensed by the Ministry of Health. They are usually small, privately owned,
and stock various medicines including prescription-based ones

General retailers

Small grocery stores and village shops that sell fast-moving consumer goods, food and provisions. They often
stock over-the-counter medicines including anti-malarial drugs but typically are not recognized as drug
stores, nor hold licenses

Itinerant drug vendors

Informal healthcare providers who are mobile and typically operate in rural areas and cover more than one village. Some are retired healthcare providers from various government ministries but are no longer registered.
They are typically not linked with regulatory authorities

Table 2 Total outlet survey sample
Eastern

Central

Western

Coastal

Total

Outlets enumerated

8432

7481

5666

7085

28,664

Outlets screened

8271

7393

5598

7005

28,267

Outlets that met screening criteria

1563

710

1149

994

4416

Outlets interviewed

1554

702

1147

992

4395

Outlets that had any anti-malarial at the time of survey

1330

594

1065

870

3859

Observing regional differences, Eastern and Central
illustrated a slightly higher market composition of CHWs
(44.3 and 44.3 %, respectively) compared to Western and
Coastal (35.0% and 31.6%, respectively). General retailers comprised the majority of the market composition
in Western (40.5%) and Central (43.7%). Itinerant drug
vendors comprised between 6.7 and 14.7% of the market
composition across regions.

Anti‑malarial market composition

Figure 2 shows the relative distribution of all outlets that
had at least one anti-malarial in stock, by region and
nationally. Estimates indicate that CHWs comprised
41.5% of the market composition, while other anti-malarial-stocking outlets were from the private sector (58.5%),
including general retailers (27.9%), itinerant drug vendors (11.8%), pharmacies (10.9%), and private for-profit
facilities (7.9%).

Naonal
N=3,859
11.8

6.7
41.5

27.9

Western
N=1,065

Central
N=594

Eastern
N=1,330

12.3

14.7
44.3

29.5

Coastal
N=870
13.7

44.3

18.8

40.5
10.9

7.9

11.2

Fig. 2 Anti-malarial market composition

8.4

12.3

9.9

31.6

35

43.7
7.5

4.6

7.7
3.2
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Availability of anti‑malarial medicines and diagnostics

Availability of anti-malarial medicines and malaria diagnostics among outlets stocking at least one anti-malarial
is shown in Tables 3 and 4. Among anti-malarial-stocking

CHWs, 83.1% stocked an ACT and 67.0% stocked chloroquine. Oral AMT was available in less than 5% of CHWs
(2.9%). Around three out of four CHWs stocked a malaria
blood test (RDT or microscopy) (77.7%). There were few

Table 3 CHW availability of anti-malarial drugs and malaria diagnostics, among anti-malarial-stocking outlets, by region
CHW
Total(N = 1263) (95% CI)

Eastern
(N = 545) (95% CI)

Central
(N = 244) (95% CI)

Western
(N = 242) (95% CI)

Coastal
N = (232) (95% CI)

Availability of anti-malarialsa
Any ACTb

83.1 (80.1, 86.1)

87.8 (83.9, 90.9)

76.2 (69.8, 81.6)

83.3 (76.1, 88.6)

91.7 (86.2, 95.1)

Chloroquine

67.0 (63.5, 70.5)

67.6 (63.0, 71.8)

65.4 (58.8, 71.4)

76.0 (68.4, 82.3)

67.3 (59.0, 74.6)

Primaquine

62.6 (58.6, 66.5)

60.3 (55.3, 65.2)

58.1 (50.4, 65.3)

72.7 (64.2, 79.8)

74.7 (67.5, 80.8)

Oral AMT

2.9 (1.6, 4.2)

2.4 (1.2, 4.7)

4.0 (2.1, 7.5)

4.5 (2.6, 7.9)

Non-oral AMT

8.9 (6.5, 11.3)

6.5 (4.1, 10.2)

12.3 (8.3, 17.8)

7.9 (5.1, 12.0)

N = 1382

0.6 (0.2, 2.2)
5.0 (2.4, 10.2)

N = 597

N = 277

N = 257

N = 251

77.7 (74.4, 81.0)

79.3 (75.5, 82.7)

72.5 (65.6, 78.4)

83.6 (78.1, 87.9)

86.1 (79.7, 90.7)

0.2 (0.0, 0.5)

0.1 (0.0, 0.7)

0.3 (0.0, 2.1)

1.1 (0.2, 5.9)

77.7 (74.4, 81.0)

79.3 (75.5, 82.7)

72.5 (65.6, 78.4)

83.6 (78.1, 87.9)

Availability of blood testingc
Any malaria
blood testing
Malaria
microscopy
RDTs

0.0
86.1 (79.7, 90.7)

AMT artemisinin monotherapy
a

Anti-malarial-stocking outlets have at least one anti-malarial in stock on the day of the survey, verified by presence of at least one anti-malarial recorded in the antimalarial audit sheet

b

At the time of the 2015/2016 Myanmar ACTwatch outlet survey, AL, DHA-PP, and ASMQ were the first-line treatments for uncomplicated falciparum malaria. There
was no ASMQ audited during the 2015/2016 survey

c
Blood testing availability is reported among outlets that either had anti-malarials in stock on the day of the survey or reportedly stocked anti-malarials in the
previous 3 months

Table 4 Private sector availability of anti-malarial drugs and malaria diagnostics, among anti-malarial-stocking outlets
Private Sector Total
N = 2596 (95% CI)

Eastern
(N = 785) (95% CI)

Central
(N = 350) (95% CI)

Western
(N = 823) (95% CI)

Coastal
N = (638) (95% CI)

Availability of anti-malarialsa
Any ACTb

41.7 (36.9, 46.6)

65.6 (59.5, 71.2)

36.7 (27.6, 46.8)

14.1 (11.2, 17.5)

19.0 (14.2, 25.0)

Chloroquine

41.8 (38.4, 45.3)

24 (20.1, 28.3)

43.5 (37.0, 50.2)

47.7 (41.6, 53.8)

68.6 (62.4, 74.2)

Primaquine
Oral AMT
Non-oral AMT

7.7 (4.9, 10.4)

7.5 (5.4, 10.4)

11.1 (6.4, 18.4)

2.9 (1.6, 5.2)

1.0 (0.5, 1.9)

27.7 (23.8, 31.7)

25.0 (18.9, 32.4)

31.4 (24.8, 38.9)

54.1 (49.4, 58.7)

15.4 (11.7, 20.2)

11 (8.6, 13.4)
N = 2890

11.7 (7.7, 17.3)

11.8 (8.6, 16.2)

18.3 (15.0, 22.2)

N = 904

N = 398

N = 877

N = 711

5.5 (3.3, 9.0)

21.0 (17.2, 25.4)

14.8 (10.4, 20.5)

8.4 (6.0, 11.7)

8.7 (5.7, 13.0)

Availability of blood testingc
Any malaria blood
testing
Malaria microscopy
RDTs

15.4 (12.6, 18.1)
0.6 (0.2, 0.9)

0.6 (0.3, 1.2)

0.7 (0.2, 2.0)

0.7 (0.3, 1.5)

0.2 (0.0, 0.8)

14.9 (12.3, 17.6)

20.5 (16.7, 24.8)

14.2 (9.9, 19.8)

8.2 (5.8, 11.4)

8.7 (5.7, 13.0)

AMT artemisinin monotherapy
a

Anti-malarial-stocking outlets have at least one anti-malarial in stock on the day of the survey, verified by presence of at least one anti-malarial recorded in the antimalarial audit sheet

b

At the time of the 2015/2016 Myanmar ACTwatch outlet survey, AL, DHA-PP, and ASMQ were the first-line treatments for uncomplicated falciparum malaria. There
was no ASMQ audited during the 2015/2016 survey

c
Blood testing availability is reported among outlets that either had anti-malarials in stock on the day of the survey or reportedly stocked anti-malarials in the
previous 3 months
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Western region (36.6%) compared to other regions which
had an ACT market share greater than 60%.
Figure 4 illustrates the market share of different categories of anti-malarial medicines sold or distributed within
seven days prior to the survey in the private sector. The
national private-sector anti-malarial market share comprised ACT (44.0%), chloroquine (26.6%), oral AMT
(19.6%). ACT market share was highest in the Eastern
region, accounting for 59.1% of the market share and lowest in Western region (17.6%). Chloroquine market share
was lowest in the Eastern region (8.3%) but similar across
other regions, ranging from 32.6 to 40.5%. Oral AMT was
distributed across all regions, and highest in the Western
region (34.5%) and lowest in the Coastal region (13.1%).
Non-oral AMT market share was less than 10% across
regions.
The relative private sector market share across outlet types is also presented, excluding contributions from
CHW (Additional file 1). In the private sector, the majority of anti-malarials were distributed by pharmacies
(39.1%). Private-for-profit facilities, general retailers and
itinerant drug vendors accounted for around 60% of the
total private sector market share (19.1, 21.8 and 20.3%,
respectively).

regional differences between indicators among CHWs
(Table 3).
ACT was available in fewer than half of the anti-malarial-stocking private sector outlets (41.7%) (Table 4). ACT
availability was highest in Eastern (65.6%), followed by
Central (36.7%), Coastal (19.0%) and Western (14.1%)
regions. Chloroquine was found in 41.8% of privatesector outlets. Chloroquine availability was highest in
Coastal (68.6%), followed by Western (47.7%), Central
(43.5%) and Eastern (24.0%). Availability of primaquine
was rare (7.7%). Oral AMT availability was found in
27.7% of the private sector, and ranged from 54.1% of
anti-malarial-stocking outlets in the Western region to
15.4% in the Coastal region. Availability of non-oral AMT
was less than 20% across the private sector, and highest in the Western region (18.3%). Malaria blood testing
was available in 15.4% of the anti-malarial-stocking private sector outlets: RDT (14.9%) rather than microscopy
(0.6%). Malaria blood testing was highest in the Eastern
region (20.5%) and lowest in the Western and Coastal
regions (<10%).
Anti‑malarial market share

Figure 3 illustrates the market share of different categories of anti-malarial medicines sold or distributed within
seven days prior to the survey among CHW. 71.6% of
the market share comprised ACT, followed by chloroquine (22.3%). Distribution of oral AMT was rare, 3.7%
of the market share. ACT market share was lowest in the

Providers’ knowledge

More than half of CHWs could correctly state the
national first-line treatment for uncomplicated falciparum and vivax malaria (59.2 and 56.9%, respectively)
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Fig. 3 Anti-malarial market share: CHW
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Fig. 4 Anti-malarial market share: Private Sector

(Table 5). Less than 20% of private-sector providers could
correctly state the first-line treatment for uncomplicated
falciparum and vivax malaria (15.8 and 13.2%, respectively) (Table 6). Region-specific differences within the

private sector were also present, where less than 7% of
providers in the Western and Coastal regions were able
to correctly state the first-line treatment. There were few
regional differences by CHW.

Table 5 CHW knowledge of the first-line treatment guidelines
CHW
Total N = 1382
(95% CI)

Eastern
(N = 597)
(95% CI)

Central
(N = 277)
(95% CI)

Western
(N = 257)
(95% CI)

Coastal
N = (251)
(95% CI)

Correctly stated national first-line
treatment for uncomplicated
falciparum malaria

59.2 (55.1, 63.2)

60.7 (55.5, 65.7)

57.2 (49.8, 64.3)

65.7 (57.9, 72.7)

51.7 (43.1, 60.3)

Correctly stated national first-line
treatment for uncomplicated
vivax malaria

56.9 (52.9, 60.9)

60.5 (55.9, 64.1)

56.9 (49.3, 64.1)

64.9 (57.0, 73.2)

50.4 (42.3, 58.5)

Proportion of providers who:

Table 6 Private sector knowledge of the first-line treatment guidelines
Private sector total
N = 2596
(95% CI)

Eastern
(N = 904)
(95% CI)

Central
(N = 398)
(95% CI)

Western
(N = 877)
(95% CI)

Coastal
N = (711)
(95% CI)

Correctly stated national first-line treatment
for uncomplicated falciparum malaria

15.8 (12.6, 19.0)

19.8 (16.7–23.3)

18.3 (12.6–26.0)

5.0 (3.3–7.4)

5.5 (3.3–8.9)

Correctly stated national first-line treatment
for uncomplicated vivax malaria

13.2 (10.5, 15.9)

14.7 (11.6, 18.4)

14.7 (10.1, 20.8)

4.3 (2.7, 6.6)

6.3 (4.2, 9.4)

Proportion of providers who:
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Table 7 CHW supervision, support and caseload reporting
CHW total %
(95% CI)

Eastern %
(95% CI)

Central %
(95% CI)

Western %
(95% CI)

Coastal %
(95% CI)

N = 1461

N = 625

N = 301

N = 264

N = 271

60.7 (57.0, 64.4)

63.4 (58.7, 67.9)

56.5 (49.5, 63.2)

66.4 (58.0, 73.8)

64.5 (56.3, 71.8)

N = 1461

N = 624

N = 301

N = 264

N = 272

59.6 (55.8, 63.4)

62.3 (57.3, 67.1)

57.3 (50.3, 64.1)

60.5 (51.4, 68.8)

60.1 (52.5, 67.3)

N = 1458

N = 626

N = 300

N = 263

N = 269

39.1 (35.8, 42.4)

59.5 (53.6, 65.0)

28.3 (23.4, 33.8)

38.6 (31.2, 46.5)

28.8 (22.4, 36.3)

N = 1461

N = 625

N = 301

N = 264

N = 271

76.5 (71.9, 80.7)

74.8 (68.4, 80.2)

82.4 (76.5, 87.1)

83.7 (75.9, 89.3)

N = 1459

N = 623

N = 301

N = 264

N = 271

76.0 (72.6, 79.3)

75.6 (70.9, 79.7)

73.5 (67.0, 79.1)

81.4 (75.3, 86.2)

81.2 (72.9, 87.4)

N = 1459

N = 623

N = 301

N = 264

N = 271

51.8 (48.1, 55.5)

40.3 (35.5, 45.2)

57.7 (51.3, 63.9)

38.1 (30.9, 45.9)

62.5 (52.8, 71.2)

N = 1459

N = 623

N = 301

N = 264

N = 271

26.2 (22.6, 29.9)

36.4 (31.3, 41.8)

19.2 (13.9, 26.0)

43.2 (35.2, 51.7)

20.0 (12.6, 30.2)

Proportion of providers who:
Trained on malaria diagnosis (RDT
and/or microscopy)

Trained on national malaria treatment guidelines

Reported receiving a supervisory
or regulatory visit within the past
year

Kept records on number of patients 77.3 (74.1, 80.6)
tested/treated for malaria

Reported numbers of patients
tested/treated for malaria to
government or NGO

Reported numbers to government

Reported numbers of to a NGO

Supportive supervision and passive surveillance

The majority of CHW (60.7%) reportedly receiving training on malaria diagnosis, and 59.6% on national malaria
treatment guidelines (Table 7). Almost 40% reportedly received a supervisory or regulatory visit within
12 months. Similarly, 77.3% reportedly kept records
on number of patients tested or treated for malaria and
76.0% said they reported these numbers to government
(51.8%) or NGOs (26.2%). There were few regional differences among CHW.
Less than 10% of private-sector outlets reportedly
received training within the past year, and supervisory/
regulatory visits were reported by only one in four providers (19.9%) (Table 8). Only 12.2% kept patient records,
and less than 10% reported to government (2.9%) or
NGOs (6.6%). Private sector region-specific differences were observed, with highest numbers in Eastern region, with almost half of private-sector providers
(47.8%) reporting supervisory/regulatory visits. However,
all other indicators were typically less than 15%, with
less than 6% outlets located in the Western and Central region reportedly receiving training on diagnosis,

national treatment guidelines, receiving a supervisory
visit, and reporting on caseload data.

Discussion
The 2015/2016 outlet survey presents, for the first time,
national estimates of the anti-malarial market among
CHWs and the private sector in Myanmar. Findings point
to a strong foundation for malaria case management
among CHWs but highlight key gaps in the private sector
as well as notable regional differences. The results also
point to the urgent need to remove oral AMT from the
private sector marketplace.
CHW readiness for appropriate malaria case management

Findings from the outlet survey illustrate the importance
of CHWs, with up to 40% of the anti-malarial service
delivery points comprising of these providers, though this
contribution is likely to be lower if public health facilities
were included in the sample. These providers were more
prevalent in Eastern areas of the country, which reflect
several MARC initiatives to scale-up these communitybased providers.
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Table 8 Private sector supervision, support and caseload reporting
Private sector total %
(95% CI)

Eastern %
(95% CI)

Central %
(95% CI)

Western %
(95% CI)

Coastal %
(95% CI)

N = 2925

N = 923

N = 400

N = 882

N = 720

12.0 (9.1, 15.7)

8.1 (4.8, 13.2)

4.8 (3.2, 7.1)

1.7 (0.9, 3.0)

N = 2924

N = 922

N = 400

N = 882

N = 720

9.4 (6.9, 11.8)

12.9 (9.7, 16.8)

9.0 (5.3, 14.8)

5.2 (3.7, 7.4)

5.3 (2.8, 9.7)

N = 2917

N = 921

N = 399

N = 879

N = 718

19.9 (17.1, 22.7)

47.8 (41.2, 54.4)

8.7 (5.6, 13.4)

2.7 (1.4, 5.2)

2.0 (1.1, 3.8)

N = 2920

N = 924

N = 397

N = 881

N = 718

12.2 (9.3, 15.2)

16.3 (13.1, 20.1)

13.3 (8.5, 20.3)

6.4 (4.2, 9.6)

3.9 (1.8, 8.4)

N = 2905

N = 921

N = 386

N = 880

N = 718

9.4 (6.7, 12.1)

13.2 (10.5, 16.6)

9.7 (5.4, 16.6)

4.5 (2.6, 7.5)

3.1 (1.2, 7.8)

N = 2905

N = 921

N = 396

N = 880

N = 718

2.9 (1.7, 4.2)

2.7 (1.7, 4.3)

3.5 (1.8, 6.6)

2.4 (1.3, 4.6)

2.3 (0.6, 7.7)

N = 2905

N = 921

N = 396

N = 880

N = 718

6.6 (4.6, 8.6)

10.4 (7.9, 13.6)

6.6 (3.6, 11.8)

2.0 (0.8, 4.8)

0.8 (0.4, 1.8)

Proportion of providers who:
Trained on malaria diagnosis 8.0 (5.9, 10.2)
(RDT and/or microscopy)

Trained on national malaria
treatment guidelines

Reported receiving a supervisory or regulatory visit
within the past year

Kept records on number of
patients tested/treated for
malaria

Reported numbers of
patients tested/treated for
malaria to government or
NGO

Reported numbers to government

Reported numbers of to a
NGO

Readiness for malaria case management implies having malaria commodities (first-line treatment for uncomplicated malaria and/or confirmatory testing) in stock at
the time of survey. The findings point to strong readiness
for appropriate malaria case management among CHWs
who were found to be stocking anti-malarials. More than
three-quarters had confirmatory testing available. Over
80% had first-line treatment for falciparum malaria in
stock and more than half had the first-line treatment for
vivax malaria. More than half of the CHW received training on national treatment guidelines and/or testing, and
over three-quarters kept malaria case load data.
These findings suggest that there is merit in expanding
and scaling-up CHWs further as a means to reach remote
communities with malaria commodities, including expansion to the Western region where malaria endemicity is
even higher than in other parts of the country. This recommendation is supported by several studies in Myanmar
which have shown the CHW programme to be relatively

inexpensive to implement [15], to have improved access to
early and reliable diagnosis and treatment among marginalized groups [16] and to have improved malaria healthcare [17]. Key challenges to be addressed include ensuring
a constant supply of first-line treatments, given over half
of the CHWs were not stocking any anti-malarials on the
day of survey or in the past 3 months. It is not clear from
this study if this finding reflects long term stock-outs or
rather inactive CHW. While over 40,000 CHW have been
deployed over the years by the government and other
partners in Myanmar, it is noteworthy that not all of these
community based providers may be tasked with the provision of malaria commodities. Moreover, there is a high
rate of attrition of CHWs and it was reported in 2015 that
only 15,000 were currently active or functional as per the
National Strategic Plan [1]. Several strategies may need
to be considered to improve retention and motivation of
CHWs, such as incentive schemes, training and supervision, and ensuring regular supply of commodities [18–21].
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National guidelines stipulate that CHWs are authorized
and recommended to provide a low dose of primaquine
(0.25 mg) once weekly for eight weeks after chloroquine
to prevent vivax malaria relapse, which has been found
to be the front-line therapy for radical cure of P. vivax
[22]. A single dose of primaquine following ACT for falciparum malaria is also recommended in the national
treatment guidelines in order to substantially reduce
transmission potential [23]. The outlet survey found that
availability of primaquine among CHW however was
moderate, around 60%. This may highlight challenges
with procurement of the medicine to maintain constant
supply, although availability of primaquine was much
higher in Myanmar than in some neighbouring ACTwatch countries [24, 25]. This gap in CHW readiness
to provide primaquine will be of importance to address
given evidence that the addition of a single dose of primaquine could have a major effect on malaria transmission from falciparum malaria patients [26].
Role of the private sector in appropriate malaria case
management

Consistent with findings from other countries in the
GMS, the private sector plays an important role in
malaria case management [24, 25]. Results from this
study show that the private-sector comprised over half
of the anti-malarial service delivery points, and this was
most notable in the Western and Coastal regions. Myanmar’s private sector was typically made up of pharmacies,
general retailers and itinerant drug vendors, all of which
were allowed to test and treat for malaria according to
national policy at the time of the survey. Private sector
market share data revealed that pharmacies distributed
most of the private sector anti-malarials, however general retailers and itinerant drug vendors were also common sources, illustrating the need to reach these types of
outlets as part of elimination strategies.
These findings have several implications for Myanmar’s malaria National Strategic Plan as it sets out to
increase regulation of several private sector outlet types,
and clamp down on outlets that are not licensed. Removing general retailers and itinerant drug vendors from the
anti-malarial market, or making it illegal for them to sell
anti-malarials or provide testing may result in a lack of
access to malaria commodities. Several success stories
have been demonstrated by the AMTR project which
has specifically included these types of outlets as part of
their strategy to promote ACT uptake through behaviour
change communication and product promoter visits [5,
6]. While it may not be feasible to scale-up or replicate
such an initiative to the entire country, ensuring that
these anti-malarial-stocking providers have constant supply and access to malaria commodities may be an initial
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step to maintain existing levels of coverage and access
to malaria treatment. Private sector training, capacity-building and demand generation will be important
strategies to complement efforts to increase coverage of
malaria commodities in the private sector [27].
Readiness and performance of the private sector

The private sector was generally less well equipped to test
and appropriately treat malaria infections compared with
CHWs. Where anti-malarials were available in the private sector, fewer than half of anti-malarial-stocking outlets had first-line treatments available for falciparum or
vivax malaria. There were, however, notable differences
in availability of first-line treatments according to different geographical areas. Availability and market share
of first-line treatment for falciparum malaria, ACT, was
more common in the Eastern region than in the Western or Coastal regions. Over 60% of the anti-malarials
distributed in Eastern Myanmar were ACT compared to
18% in the Western region. These findings are most likely
attributable to several initiatives, including the AMTR
project, which has included intensified activities across
the Eastern part of Myanmar to increase demand and
uptake of ACT, as previously mentioned.
Availability of malaria blood testing in the private sector was generally low, with 15% or less of outlets having
RDT or microscopy available. These gaps in private sector readiness are a threat to appropriate management of
suspected cases, given the real likelihood of presumptive
anti-malarial treatment. In particular, while the market
share data suggest that over 70% of anti-malarials distributed in the week prior to the survey were first-line
treatments for falciparum or vivax malaria in the private
sector, it is highly likely that most of these were given
presumptively as providers did not have access to malaria
tests. Without diagnostic blood tests, providers had no
reliable way of differentiating the types of malaria infections. As the national malaria treatment guidelines are
different for falciparum and vivax malaria, adhering to
national treatment guidelines was inherently impossible
for most private sector providers in the absence of confirmatory testing.
As the malaria National Strategic Plan stipulates universal coverage of malaria testing, several strategies are
needed to scale-up coverage of diagnostics, including
efforts that are already underway as part of the AMTR
project to promote access of RDTs in the private sector. Strategies may include the provision of training and
supervision to administer parasitological testing, as well
as incentive models for providers, and maintaining constant supply of RDTs [28]. From the demand side this will
require promoting RDTs as an important commodity for
which patients are willing to pay for [29]. In fact, evidence
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suggests that the introduction of RDTs in Myanmar may
be highly acceptable, even among the informal private
sector, and could serve to promote provider empowerment and improve patient-provider relationships [30].
Other research has shown successful outcomes after
introducing RDTs in the private sector [31, 32]. However,
challenges with adhering to different treatment regimens
for falciparum and vivax malaria based on RDT results,
as well as a focus on what to do for a negative RDT result,
are indicative of the need to promote training and supervision in light of any large-scale roll-out of RDTs in the
private sector [33]. Lessons learnt from Cambodia’s experience of introducing RDTs in the private sector may be
useful to review in light of any national scale-up of RDTs
across Myanmar [28].
Private sector availability and distribution of oral
artemisinin monotherapy

Oral AMT poses a serious threat to the continued efficacy of artemisinins in Myanmar and across the GMS.
Since 2008, the WHO has called for a ban on this monotherapy, and in 2012 Myanmar followed suit with other
countries in the GMS, issuing a ban on the importation of
oral AMT. However, data point to the widespread availability and distribution of this anti-malarial in the private
sector, accounting for one in every four anti-malarials
distributed. Results were most concerning across the
Western region of the country, where one in three outlets were found to have oral AMT in stock, accounting
for 34.5% of the market share. Oral AMT was also most
commonly distributed among itinerant drug vendors,
although other outlet types play an important role.
While several initiatives have been in place in Eastern
Myanmar to remove this from the market, results point
to the fact that oral AMT persists, with 25% of outlets
stocking this in 2015/2016, an overall 17-point percentage increase from the previous sub-national survey
implemented in project intervention areas of Eastern
Myanmar [6]. The reasons for this increase are unclear. It
is postulated that increases may be due to profit margins
obtained from oral AMT versus highly subsided ACT, or
a push by providers and manufactures to sell soon to be
expired stock, or/and consumer demand for this medicine [34]. This may also reflect low levels of provider
awareness about recommended first-line treatments
and/or beliefs and preferences for non-first-line medicines [35–37]. Further research is being implemented to
understand provider perceptions around oral AMT as a
means to explain stocking and dispensing practices.
Perhaps of gravest concern is the possibility that actual
market share of oral AMT was higher than estimated by
the survey. The ACTwatch outlet survey analysis assumes
a full course AETD to calculate the basic unit for market
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share. However, in reality the actual sale to patients may
be less than a full course treatment. In Myanmar where
ACT was commonly sold as full course treatments, the
situation is rather different with oral AMT, which was
typically dispensed as one or two tablets to a patient
instead of the full AETD of 19.2 tablets with which oral
AMT market share is calculated. Therefore, the proportion of patients that are treated with oral AMT relative
to other types of anti-malarials is likely much higher than
the market share estimated using AETDs distributed.
The results from this survey point to the fact that oral
AMT remains a serious public health concern in Myanmar. Several reasons for the persistent availability and
sale of this medicine have been postulated, including a
relatively lenient ban which allows distributors to continue to import and sell this drug [6]. Action is urgently
required to address this finding of grave public health
significance.
Provider knowledge

Provider knowledge was generally lower in the private
sector compared to CHWs, with slightly fewer than half
of these providers knowing the first-line treatment for
either falciparum or vivax malaria. Other studies have
shown that provider knowledge of medicines and doses,
particularly in the private sector, is often poor [38, 39].
Indeed, in the private sector, knowledge was less than
20% and exceptionally low in the Western region, where
less than 5% of providers could correctly state the firstline treatment for falciparum or vivax malaria. This
speaks to the need to promote provider awareness of
the first-line treatment regimens for falciparum or vivax
malaria.
Increasing provider knowledge may be a first step
towards ensuring the delivery of first-line treatments.
That said, some studies have found no evidence of a
relationship between providers’ knowledge and practice, and have suggested that provider preference is a
stronger predictor of appropriate case management
practices [40]. As such, simply increasing knowledge
of the first-line treatment may have a limited effect, as
supported by other studies [41–43]. This points to the
importance of designing interventions that strive to
change what providers think and believe to be appropriate, not only to enhance what they know. This could be
complemented with widespread behaviour change communication, alerting communities to the first-line treatments, to the importance of receiving a confirmatory
test prior to treatment, and dangers of oral AMT and
sub-clinical dosing. Such multi-pronged strategies will
be important in Myanmar to accelerate universal coverage of confirmatory testing and appropriate malaria
treatment.
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Supervision and malaria caseload reporting

Overall private sector supervision, training on either
national guidelines or diagnostic testing was low with fewer
than one in five providers reporting these activities. The
exception to this was in the Eastern region, where over half
of the providers received a supervisory visit. This is most
likely attributable to the AMTR supporting interventions,
which includes routine visits from product promoters to
pharmacies, general retailers and itinerant drug vendors.
These important benchmarks will be useful to guide
future national strategy, which has proposed that the
anti-malarial-stocking private sector should report on
caseload data. Motivating these private-sector outlets
will be key to ensure they report on testing and treatment outcomes. However, there are notable challenges
with private sector caseload reporting, including a lack of
provider incentives and operation of this sector outside
the National Health Management Information Services
(HMIS) [44]. Of promise is that several private sector initiatives are in place to do this, including the GMS
Elimination of Malaria through Surveillance Programme
(GEMS) which aims to actively increase malaria testing,
treatment and reporting in the private sector through
training, supervision and surveillance [45]. Caseload data
from the private sector will be integrated with public sector data to provide national programmes with a more
complete picture of malaria burden to respond to all
detected cases.
Study limitations

Some limitations are acknowledged. First, as the study
excluded public health facilities due to operational constraints, the total anti-malarial market for the whole
country could not be estimated. A follow-up survey that
includes public health facilities would be useful to explore
the readiness of the public sector and allow for the total
anti-malarial market share to be calculated. Second, as the
survey was cross-sectional it could not track the actual
movement of drug stocks at the outlets. For this reason,
all market share calculations were based on reported sales
within one week and were subject to recall bias and volatility of the market. Lastly, the data collection period spanned
more than four months from the end of August 2015 to
early January 2016, and anti-malarial markets might have
shifted during that time due to seasonal variations.
Regardless of the aforesaid limitations, the study was
the first to produce national estimates of the anti-malarial
market among CHWs and the private sector in Myanmar.
As Myanmar has the highest burden of malaria cases in
GMS and moves towards malaria elimination, the need
for a comprehensive picture of entire malaria testing and
treatment landscape was never more pressing.
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Conclusions
Results from this study suggest there are key gaps in
private-sector readiness for appropriate malaria case
management, and to some extent these gaps are also
observed among CHWs. Availability of first-line treatments and malaria diagnostic tests was moderately high
among the CHWs. These providers may be an important channel to reach remote rural communities, but it
will be necessary to maintain constant supply of commodities to ensure universal coverage of confirmatory
testing and national first-line treatment. The private
sector remains responsible for most of malaria testing and treatment in Myanmar, and while most of the
anti-malarials distributed were first-line treatments,
availability of confirmatory testing was rare, meaning
that most patients are being treated presumptively with
either chloroquine or ACT. Of great urgency is the need
to remove the widespread availability and distribution
of oral AMT, which threatens global progress towards
malaria control and case management. Poor privatesector knowledge, combined with lack of training or
supervision, further compounds the situation. While
several strategies have focused on strengthening the private sector in the eastern part of the country, and results
from the private sector in this area are more promising,
these strategies must be intensified and scaled up, using
a multipronged approach to promote both provider and
consumer behaviour change. Future policies and interventions on malaria control and elimination in Myanmar should take these factors into consideration across
all phases of implementation.
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